Engineered regulatory T cell development project 001
Research type
Research Study
Full title
Investigation of white blood cells to support the development of engineered regulatory T cell therapies
IRAS ID
273838
Contact name
Marc Martinez-Llordella
Contact email
Sponsor organisation
Quell Therapeutics Limited
Duration of Study in the UK
4 years, 11 months, 28 days
Research summary
Regulatory T cells are an important part of the immune system where they act to prevent inappropriate or excessive immune responses. They are therefore an interesting target in conditions that result from issues with the immune system.
Quell Therapeutics is interested in developing medicines based on regulatory T cells. The cells can be genetically engineered to introduce new functions to the cells. The purpose of this research will be to understand what regulatory T cells are and how they can be engineered to generate effective medicines for future use in patients. It will also concentrate on ways to manufacture the engineered cells and methods to analyse them.
REC name
London - Hampstead Research Ethics Committee
REC reference
19/LO/1920
Date of REC Opinion
17 Dec 2019
REC opinion
Favourable Opinion